AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026260300
Cite this article
12
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas

Aneta Borkowska1†* ,  Teresa Szczepińska2† ,  Michał Sitek2 ,  Wiktoria Trynkos2 ,  Izabela Ziuzia-Graczyk2 ,  Anna Staniszewska3 ,  Łukasz Kuryk1,4 ,  Deepak Kala5 ,  Deepak Kala5 ,  Ewelina Holm Bidstrup2 ,  Ewelina Holm Bidstrup2 ,  Piotr Rutkowski1 ,  Monika Staniszewska2*
Show Less
1 Department of Soft Tissue, Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Masovia , Poland
2 Centre for Advanced Materials and Technologies CEZAMAT, Warsaw University of Technology, Warsaw, Masovia , Poland
3 Central Clinical Hospital, Medical University of Warsaw, Warsaw, Masovia , Poland
4 National Institute of Public Health-National Institute of Hygiene, Warsaw, Masovia , Poland
5 Centera Tetrahertz Laboratory, Institute of High-Pressure Physics, Polish Academy of Sciences, Warsaw, Masovia , Poland
†These authors contributed equally to this work.
Received: 22 June 2026 | Revised: 2 August 2026 | Accepted: 4 September 2026 | Published online: 16 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: Soft tissue sarcomas (STS) are rare cancers without validated biomarkers for monitoring or prognosis. Liquid biopsy (LB) enables minimally invasive tumor tracking.

Objectives: This study aims to identify prognostic biomarkers in STS by assessing whether copy number variations (CNVs) of key genes correlate with outcomes, enabling early risk stratification and monitoring.

Methods: We conducted a preliminary longitudinal CNV analysis in plasma cell-free DNA from 19 patients using droplet digital polymerase chain reaction, measuring CNVs at multiple treatment stages (B1–B6). Statistical analyses were performed in R (v.4.4.3). Continuous variables are shown as median (interquartile range), and categorical variables as counts (%). Benjamini–Hochberg adjustment was applied, and progression-free survival (PFS) was analyzed using Kaplan–Meier and the log-rank test.

Results: Associations between CNVs and tumor size, necrosis, treatment response, disease progression, and PFS were observed. B1–B4 showed interconnected CNVs, involving TP53, RB1, MDM2, BRAF, MET, and HSP90. Progression may be associated with elevated CNVs for MDM2 and MET during chemotherapy (B2), and for TP53, RB1, MDM2, and HSP90 following radiotherapy (B3). At baseline, MDM2 CNV was higher in non-responders and increased during therapy in patients who subsequently experienced progression, which may be associated with poorer response to chemotherapy and radiotherapy. A p-value minimization framework suggested gene-specific CNV thresholds at B2 and B3, with higher CNV linked to shorter PFS.

Conclusion: Longitudinal LB profiling indicates that genomic changes in STS are linked to outcomes and resistance. MDM2 emerged as a potential biomarker. Given the small, exploratory study cohort, these findings need cautious interpretation and validation in larger groups.

Graphical abstract
Keywords
Soft tissue sarcoma
Liquid biopsy
Biomarkers
Progression
Copy number variations
Progression-free survival
Funding
This research was funded by NCN (2023/49/B/NZ5/03294) and POB Biotechnology and Biomedical Engineering of Warsaw University of Technology within the Excellence Initiative: Research University (IDUB) programme (LIDER POB BIB-2 nr CPR-IDUB/73/Z01/POB4/2024 [22.03.2024]).
Conflict of interest
The authors declare they have no competing interests.
References
  1. Williams TP, Grignol VP. Circulating biomarkers in sarcoma. Curr Oncol Rep. 2025;27(8):1013-1018. doi: 10.1007/s11912-025-01692-0
  2. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353(7):701-711. doi: 10.1056/NEJMra041866
  3. Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018;243(3):213-221. doi: 10.1177/1535370217750088
  4. Sharma SR, Paonessa NE, Casadei L, Costas De Faria F, Pollock RE, Grignol V. Clinical biomarkers in soft tissue sarcoma: a comprehensive review of current soft tissue sarcoma biomarkers. J Surg Oncol. 2022;125(2):239-245. doi: 10.1002/jso.26680
  5. Grasso D, Marzocchi B, Scoccianti G, et al. Untargeted metabolomics and liquid biopsy investigation of circulating biomarkers in soft tissue sarcoma. Cancers (Basel). 2025;17(3):553. doi: 10.3390/cancers17030553
  6. Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z. Application of liquid biopsy in bone and soft tissue sarcomas: present and future. Cancer Lett. 2018;439:66-77. doi: 10.1016/j.canlet.2018.09.012
  7. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094
  8. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926-930. doi: 10.1126/science.aar3247
  9. Snow A, Chen D, Lang JE. The current status of the clinical utility of liquid biopsies in cancer. Expert Rev Mol Diagn. 2019;19(11):1031-1041. doi: 10.1080/14737159.2019.1664290
  10. Aiyer S, Kim TH, Collier K, et al. Unlocking the potential of ctDNA in sarcomas: a review of recent advances. Cancers (Basel). 2025;17(6):1040. doi: 10.3390/cancers17061040
  11. Coombs CC, Dickherber T, Crompton BD. Chasing ctDNA in patients with sarcoma. Am Soc Clin Oncol Educ Book. 2020;40:e351-e360. doi: 10.1200/EDBK_280749
  12. Przybyl J, Chabon JJ, Spans L, et al. Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma. Clin Cancer Res. 2018;24(11):2688-2699. doi: 10.1158/1078-0432.CCR-17-3704
  13. Braig D, Becherer C, Bickert C, et al. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas. Int J Cancer. 2019;145(4):1148-1161. doi: 10.1002/ijc.32216
  14. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19(2):43-51. doi: 10.1016/j.tcb.2008.11.003
  15. Capdevila P, Carrasco C, Diaz-Beveridge R. Risk stratification in soft-tissue sarcoma using Sarculator: a single-center experience. ESMO Rare Cancers. 2025;4:100114. doi: 10.1016/j.esmorc.2025.100114
  16. Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
  17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. Springer; 2010.
  18. Nathan H, Raut CP, Thornton K, et al. Predictors of survival after resection of retroperitoneal sarcoma. Ann Surg. 2009;250(6):970-976. doi: 10.1097/sla.0b013e3181b25183
  19. Massarweh NN, Dickson PV, Anaya DA. Soft tissue sarcomas: staging principles and prognostic nomograms. J Surg Oncol. 2015;111(5):532-539. doi: 10.1002/jso.23851
  20. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii102-iii112. doi: 10.1093/annonc/mdu254
  21. Callegaro D, Miceli R, Mariani L, Raut CP, Gronchi A. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer. 2017;123(15):2802-2820. doi: 10.1002/cncr.30721
  22. Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010;16(7):781-787. doi: 10.1038/nm.2174
  23. Casadei L, Calore F, Braggio DA, et al. MDM2 derived from dedifferentiated liposarcoma extracellular vesicles induces MMP2 production from preadipocytes. Cancer Res. 2019;79(19):4911-4922. doi: 10.1158/0008-5472.CAN-19-0203
  24. Bill KLJ, Seligson ND, Hays JL, et al. Degree of MDM2 amplification affects clinical outcomes in dedifferentiated liposarcoma. Oncologist. 2019;24(7):989-996. doi: 10.1634/theoncologist.2019-0047
  25. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell. 2006;21(3):307-315. doi: 10.1016/j.molcel.2006.01.020
  26. Manfredi JJ. Mdm2 and MdmX: partners in p53 destruction. Cancer Res. 2021;81(7):1633-1634. doi: 10.1158/0008-5472.CAN-21-0145
  27. Yao Y, Zhang Q, Li Z, Zhang H. MDM2: current research status and prospects of tumor treatment. Cancer Cell Int. 2024;24(1):170. doi: 10.1186/s12935-024-03356-8
  28. Fontecha MB, Del Rosario Anadón M, Lahitou IMM, et al. Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia. Leuk Res. 2025;149:107644. doi: 10.1016/j.leukres.2025.107644
  29. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453-3459. doi: 10.1093/nar/26.15.3453
  30. Oliner JD, Saiki AY, Caenepeel S. The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 2016;6(6):a026336. doi: 10.1101/cshperspect.a026336
  31. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358(6381):80-83. doi: 10.1038/358080a0
  32. Su Q, Hou J, Du X, et al. The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma. Oncol Rev. 2025;19:1615111. doi: 10.3389/or.2025.1615111
  33. Chen N, Zhang Q, Sun L, et al. Comprehensive study of gene fusions in sarcomas. Invest New Drugs. 2025;43(1):3-17. doi: 10.1007/s10637-024-01486-4
  34. Liu Y, Li C, Liu H, Tan S. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress. Arch Pharm Res. 2024;47(5):442-464. doi: 10.1007/s12272-024-01494-1
  35. Shim BY, Yoo J, Lee YS, Hong YS, Kim HK, Kang JH. Prognostic role of Rb, p16, cyclin D1 proteins in soft tissue sarcomas. Cancer Res Treat. 2010;42(3):144-150. doi: 10.4143/crt.2010.42.3.144
  36. Yang Z, Carrio-Cordo P, Baudis M. Copy number variation heterogeneity reveals biological inconsistency in hierarchical cancer classifications. Mol Cytogenet. 2024;17(1):26. doi: 10.1186/s13039-024-00692-2
  37. Lei C, Zang H, Zhang H, et al. RNA-based next-generation sequencing strategy for screening MDM2-amplified sarcomas. Sci Rep. 2026;16(1):16402. doi: 10.1038/s41598-026-46618-3
  38. Calore F, Casadei L, Sarchet PD, et al. Extracellular vesicle-MDM2-DNA as a potential liquid biopsy biomarker for disease identification in retroperitoneal liposarcoma. Ann Surg. 2025;281(6):1048-1054. doi: 10.1097/SLA.0000000000006345
  39. Huber C, Zinserling J, Benda N, Vetter T, Rueckbeil M. Methodological insights on biomarker-based patient selection: a review of scientific advice procedures at the European Medicines Agency. Clin Pharmacol Ther. 2025;117(5):1226-1235. doi: 10.1002/cpt.3558
  40. Wang Y, Fujiwara T, Kurozumi T, et al. Advances in liquid biopsy for bone and soft-tissue sarcomas. Int J Clin Oncol. 2025;30(9):1722-1733. doi: 10.1007/s10147-025-02813-2
  41. Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348-1365. doi: 10.1016/j.annonc.2021.07.006
  42. Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv51-iv67. doi: 10.1093/annonc/mdy096
  43. Spałek MJ, Koseła-Paterczyk H, Borkowska A, et al. Combined preoperative hypofractionated radiotherapy with doxorubicin-ifosfamide chemotherapy in marginally resectable soft tissue sarcomas: results of a phase 2 clinical trial. Int J Radiat Oncol Biol Phys. 2021;110(4):1053-1063. doi: 10.1016/j.ijrobp.2021.02.019
  44. Stergioula A, Kormas T, Kokkali S, et al. What is the prognostic value of the pathologic response after neoadjuvant radiotherapy in soft tissue sarcoma? An institutional study using the EORTC-STBSG response score. Cancers (Basel). 2024;16(20):3449. doi: 10.3390/cancers16203449
  45. Spałek MJ, Borkowska AM, Telejko M, et al. The feasibility study of hypofractionated radiotherapy with regional hyperthermia in soft tissue sarcomas. Cancers (Basel). 2021;13(6):1332. doi: 10.3390/cancers13061332
  46. Laurini JA. Protocol for the Examination of Specimens From Patients With Soft Tissue Tumors. College of American Pathologists; June 2021. Accessed October 13, 2026. https://www.cap.org/wp-content/uploads/protocols/Soft.Tissue.Bx_4.1.0.0.REL_CAPCP_R.pdf?download=true
  47. Wardelmann E, Haas RL, Bovée JV, et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur J Cancer. 2016;53:84-95. doi: 10.1016/j.ejca.2015.09.021
  48. Schaefer IM, Hornick JL, Barysauskas CM, et al. Histologic appearance after preoperative radiation therapy for soft tissue sarcoma: assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group response score. Int J Radiat Oncol Biol Phys. 2017;98(2):375-383. doi: 10.1016/j.ijrobp.2017.02.087
  49. Schmiester M, Freytag A, Gillissen B, et al. Genomic evolution of high-risk soft tissue sarcomas under thermo- and chemotherapeutic selection pressure. Int J Hyperthermia. 2025;42(1):2573753. doi: 10.1080/02656736.2025.2573753
  50. Hernandez-Monge J, Martínez-Sánchez M, Rousset-Roman A, Medina-Medina I, Olivares-Illana V. MDM2 regulates RB levels during genotoxic stress. EMBO Rep. 2021;22(1):e50615. doi: 10.15252/embr.202050615
  51. Wei H, Zhang Y, Jia Y, et al. Heat shock protein 90: biological functions, diseases, and therapeutic targets. MedComm (2020). 2024;5(2):e470. doi: 10.1002/mco2.470
  52. Zhang J, He P. In silico and in vitro assessment of TP53, ATM, RAD51, and BAX genes in gastric cancer and their contribution to radiotherapy resistance. Hereditas. 2025;162(1):125. doi: 10.1186/s41065-025-00496-3
  53. Vargas R, Petty A, Lindner DJ, et al. Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer. NPJ Precis Oncol. 2025;9(1):290. doi: 10.1038/s41698-025-01063-9
  54. Kim YJ, Kim M, Park HK, et al. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology. Lab Invest. 2019;99(9):1309-1320. doi: 10.1038/s41374-019-0263-4
  55. Steele CD, Pillay N. The genomics of undifferentiated sarcoma of soft tissue: progress, challenges and opportunities. Semin Cancer Biol. 2020;61:42-55. doi: 10.1016/j.semcancer.2019.11.009

 

Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing